BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 30176944)

  • 1. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
    Wu J; Li X; Teng X; Rubin DL; Napel S; Daniel BL; Li R
    Breast Cancer Res; 2018 Sep; 20(1):101. PubMed ID: 30176944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: Usefulness of breast MRI computer-aided detection and diagnosis.
    Ku YJ; Kim HH; Cha JH; Shin HJ; Chae EY; Choi WJ; Lee HJ; Gong G
    J Magn Reson Imaging; 2018 Mar; 47(3):760-766. PubMed ID: 28675570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
    Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
    Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
    Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.
    Wu J; Li B; Sun X; Cao G; Rubin DL; Napel S; Ikeda DM; Kurian AW; Li R
    Radiology; 2017 Nov; 285(2):401-413. PubMed ID: 28708462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: Model discovery and external validation.
    Wu J; Sun X; Wang J; Cui Y; Kato F; Shirato H; Ikeda DM; Li R
    J Magn Reson Imaging; 2017 Oct; 46(4):1017-1027. PubMed ID: 28177554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase.
    Tang WJ; Kong QC; Cheng ZX; Liang YS; Jin Z; Chen LX; Hu WK; Liang YY; Wei XH; Guo Y; Jiang XQ
    Eur Radiol; 2022 Feb; 32(2):864-875. PubMed ID: 34430998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between
    Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y
    Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
    Pruneri G; Vingiani A; Bagnardi V; Rotmensz N; De Rose A; Palazzo A; Colleoni AM; Goldhirsch A; Viale G
    Ann Oncol; 2016 Feb; 27(2):249-56. PubMed ID: 26598540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients.
    Fan M; Xia P; Liu B; Zhang L; Wang Y; Gao X; Li L
    Breast Cancer Res; 2019 Oct; 21(1):112. PubMed ID: 31623683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
    Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
    BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
    Jamiyan T; Kuroda H; Yamaguchi R; Nakazato Y; Noda S; Onozaki M; Abe A; Hayashi M
    Breast Cancer; 2020 Sep; 27(5):880-892. PubMed ID: 32222891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics.
    Balkenhol MC; Ciompi F; Świderska-Chadaj Ż; van de Loo R; Intezar M; Otte-Höller I; Geijs D; Lotz J; Weiss N; de Bel T; Litjens G; Bult P; van der Laak JA
    Breast; 2021 Apr; 56():78-87. PubMed ID: 33640523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.